Investor Alert

New York Markets Open in:

Iovance Biotherapeutics Inc.

NAS: IOVA

GO
/marketstate/country/us

After Hours

/zigman2/quotes/206632254/composite

$

13.10

Change

+0.05 +0.38%

Volume

Volume 53,571

Aug 16, 2022, 7:59 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/206632254/composite

Previous close

$ 12.85

$ 13.05

Change

+0.20 +1.56%

Day low

Day high

$12.51

$13.28

Open
Open: 12.88

52 week low

52 week high

$6.18

$27.96

Open

Market cap

$2.03B

Average volume

4.22M

P/E ratio

N/A

Rev. per Employee

N/A

EPS

-2.40

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/iova

MarketWatch News on IOVA

  1. Biotech Stocks Are Up by Double Digits. It's Still a Bear Market.

    8:48 a.m. July 25, 2022

    - Barron's Online

  2. 5 Beaten-Up Biotech Stocks Saw Big Share Purchases

    4:11 a.m. June 14, 2022

    - Barron's Online

  3. Iovance Biotherapeutics stock price target cut to $20 from $29 at Truist

    7:14 a.m. May 27, 2022

    - Tomi Kilgore

  4. Iovance Biotherapeutics stock price target cut to $13 from $26 at Stifel Nicolaus

    6:52 a.m. May 27, 2022

    - Tomi Kilgore

  5. Iovance Biotherapeutics upgraded to buy from hold at Stifel Nicolaus

    7:55 a.m. Jan. 28, 2022

    - Tomi Kilgore

  6. Iovance Reports Cancer Drug Data That Looks Positive

    11:09 a.m. June 29, 2021

    - Barron's Online

  7. Biotech M&A Has Been Slow This Year. Why It Might Get Busier.

    8:32 a.m. May 21, 2021

    - Barron's Online

  8. Iovance Stock Falls Almost 40% on Double Dose of Bad News

    8:46 a.m. May 20, 2021

    - Barron's Online

  9. Iovance Biotherapeutics stock price target cut to $30 from $55 at Mizuho

    6:54 a.m. May 20, 2021

    - Tomi Kilgore

  10. Iovance Biotherapeutics started at buy with $50 stock price target at Truist

    8:15 a.m. May 3, 2021

    - Tomi Kilgore

  11. Iovance Biotherapeutics started at buy with $61 stock price target at Mizuho

    7:34 a.m. April 22, 2020

    - Tomi Kilgore

  12. The massive decline in the S&P 500 is probably already overdone

    2:21 p.m. Feb. 27, 2020

    - Lawrence G. McMillan

  13. Iovance Biotherapeutics started at buy with $27 stock price target at Stifel Nicolaus

    7:49 a.m. Oct. 1, 2019

    - Tomi Kilgore

  14. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/iova

Other News on IOVA

  1. Warning: IOVA is at high risk of performing badly

    5:30 a.m. Aug. 16, 2022

    - Seeking Alpha

  2. Replimune: Recent Developments Strengthen Bull Thesis

    6:26 p.m. Aug. 12, 2022

    - Seeking Alpha

  3. Top 5 2nd Quarter Trades of Biondo Investment Advisors, LLC

    7:00 p.m. Aug. 11, 2022

    - GuruFocus.com

  4. Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track

    12:13 p.m. Aug. 5, 2022

    - Zacks.com

  5. Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss

    7:19 p.m. Aug. 4, 2022

    - Seeking Alpha

  6. Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

    6:20 a.m. July 22, 2022

    - Zacks.com

  7. Iovance: TIL Cell Therapy Set To Prove Itself

    4:43 p.m. July 11, 2022

    - Seeking Alpha

  8. Why Iovance Stock Leaped 17% Higher Today

    6:52 p.m. June 3, 2022

    - Motley Fool

  9. Iovance climbs over 15% after multiple insider purchases

    12:14 p.m. June 3, 2022

    - Seeking Alpha

  10. Why Iovance Biotherapeutics Was Halved Today

    1:08 p.m. May 27, 2022

    - Motley Fool

  11. AVDL, SIGA, PSHG and IOVA among mid-day movers

    12:56 p.m. May 27, 2022

    - Seeking Alpha

  12. Iovance sheds half of market cap after melanoma data

    11:37 a.m. May 27, 2022

    - Seeking Alpha

  13. Loading more headlines...

Earnings Announcement

/news/pressrelease/company/us/iova

Press Releases on IOVA

  1. Iovance Biotherapeutics to Present at Upcoming Conferences

    4:01 p.m. June 8, 2022

    - GlobeNewswire

  2. Loading more headlines...

Rates »

Link to MarketWatch's Slice.